SciELO - Scientific Electronic Library Online

 
vol.100 issue9Uselfulness of ultrasonography in diagnosing patients suspect for digestive tract neoplasmsDifficulties and controversies in hospitalized patients with lower gastrointestinal bleeding author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Española de Enfermedades Digestivas

Print version ISSN 1130-0108

Abstract

FERNANDEZ PEREZ, F. J. et al. Splanchnic hemodynamic effects of somatostatin and octreotide in cirrhotic patients: A Doppler ultrasonographic study. Rev. esp. enferm. dig. [online]. 2008, vol.100, n.9, pp.552-559. ISSN 1130-0108.

Aim: Doppler-ultrasound assessment of the splanchnic hemodynamic effects of intravenous somatostatin and octreotide administration. Material and method: forty-five cirrhotic patients with esophageal varices were randomized to receive 1-hour intravenous somatostatin (SOM, 250 µg), octreotide (OCT, 50 µg), or placebo (PLA). In baseline and at 15, 30, 45 and 60 minutes of infusion, mean velocity, congestion index, flow volume and diameter of the portal vein, as well as the superior mesenteric artery resistivity index, were measured. Plasma bradykinine and vasoactive intestinal peptide (VIP) concentrations were also measured at baseline and at 30 and 60 minutes. Results: while placebo caused no changes in any of the venous and arterial parameters, SOM and OCT caused a sustained decrease in portal vein velocity (-19.41 vs. -11.19%) and flow (-22.79 vs. -12.33%), and an increase in the congestion index (+17.5 vs. +7.5%) and resistivity index of the superior mesenteric artery (+7.18 vs. +6.16%) from baseline (p < 0.05). These changes were already evident at 15 minutes and remained unchanged over the study period. With respect to OCT, SOM caused a higher reduction in mean velocity and flow in the portal vein, with no significant differences for congestion index and mesenteric artery resistivity index, both increased by SOM and OCT. Plasma bradykinine and VIP concentrations remained unchanged in the three groups. Conclusions: at therapeutic doses, intravenous somatostatin and octreotide reduce portal vein velocity and flow, and increase portal vein congestion index and superior mesenteric artery resistivity index. Somatostatin causes a higher portal flow reduction than octreotide in spite of a similar splanchnic arterial effect.

Keywords : Portal hypertension; Liver cirrhosis; Doppler ultrasonography; Somatostatin; Octreotide; Vasoactive intestinal peptide (VIP); Bradykinine.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License